{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:12:54Z","timestamp":1791987174260,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T00:00:00Z","timestamp":1595721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T00:00:00Z","timestamp":1595721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100016275","name":"SNUBH","doi-asserted-by":"crossref","award":["13-2017-002"],"award-info":[{"award-number":["13-2017-002"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10549-020-05811-2","type":"journal-article","created":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T06:02:31Z","timestamp":1595743351000},"page":"697-704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer"],"prefix":"10.1007","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-906X","authenticated-orcid":false,"given":"Se Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soomin","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumin","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murim","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-3620","authenticated-orcid":false,"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,26]]},"reference":[{"issue":"6","key":"5811_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"5811_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523\u2013533. https:\/\/doi.org\/10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"issue":"7437","key":"5811_CR3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature11881","volume":"494","author":"MB Burns","year":"2013","unstructured":"Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494(7437):366","journal-title":"Nature"},{"issue":"1","key":"5811_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13058-014-0498-3","volume":"17","author":"RS Harris","year":"2015","unstructured":"Harris RS (2015) Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Res 17(1):8. https:\/\/doi.org\/10.1186\/s13058-014-0498-3","journal-title":"Breast Cancer Res"},{"issue":"8","key":"5811_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/jnci\/djt018","volume":"105","author":"J Long","year":"2013","unstructured":"Long J, Delahanty RJ, Li G, Gao YT, Lu W, Cai Q, Xiang YB, Li C, Ji BT, Zheng Y, Ali S, Shu XO, Zheng W (2013) A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst 105(8):573\u2013579. https:\/\/doi.org\/10.1093\/jnci\/djt018","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"5811_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/ajco.13107","volume":"15","author":"M Hashemi","year":"2019","unstructured":"Hashemi M, Moazeni-Roodi A, Taheri M (2019) Association of APOBEC3 deletion with cancer risk: a meta-analysis of 26225 cases and 37201 controls. Asia-Pac J Clin Oncol 15(6):275\u2013287. https:\/\/doi.org\/10.1111\/ajco.13107","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"1","key":"5811_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13058-016-0717-1","volume":"18","author":"WX Wen","year":"2016","unstructured":"Wen WX, Soo JS-S, Kwan PY, Hong E, Khang TF, Mariapun S, Lee CS-M, Hasan SN, Rajadurai P, Yip CH (2016) Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Breast Cancer Res 18(1):56","journal-title":"Breast Cancer Res"},{"issue":"1","key":"5811_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12920-019-0579-3","volume":"12","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wen W, Bao J, Kuhs KL, Cai Q, Long J, Shu XO, Zheng W, Guo X (2019) Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types. BMC Med Genomics 12(1):131. https:\/\/doi.org\/10.1186\/s12920-019-0579-3","journal-title":"BMC Med Genomics"},{"issue":"9","key":"5811_CR9","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1073\/pnas.1424869112","volume":"112","author":"DW Cescon","year":"2015","unstructured":"Cescon DW, Haibe-Kains B, Mak TW (2015) APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci USA 112(9):2841\u20132846","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"5811_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S, International TWG (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259\u2013271. https:\/\/doi.org\/10.1093\/annonc\/mdu450","journal-title":"Ann Oncol"},{"issue":"8","key":"5811_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","volume":"23","author":"T Phillips","year":"2015","unstructured":"Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny J Jr, Taylor C, Zhang X (2015) Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol 23(8):541\u2013549. https:\/\/doi.org\/10.1097\/PAI.0000000000000256","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"7637","key":"5811_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541(7637):321\u2013330. https:\/\/doi.org\/10.1038\/nature21349","journal-title":"Nature"},{"issue":"3","key":"5811_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","volume":"24","author":"LA Emens","year":"2018","unstructured":"Emens LA (2018) Breast cancer immunotherapy: facts and hopes. Clin Cancer Res 24(3):511\u2013520. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3001","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5811_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/ng.2955","volume":"46","author":"S Nik-Zainal","year":"2014","unstructured":"Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, Davies HR, Knappskog S, Martin S, Papaemmanuil E, Ramakrishna M, Shlien A, Simonic I, Xue Y, Tyler-Smith C, Campbell PJ, Stratton MR (2014) Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet 46(5):487\u2013491. https:\/\/doi.org\/10.1038\/ng.2955","journal-title":"Nat Genet"},{"issue":"1","key":"5811_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.celrep.2015.08.066","volume":"13","author":"M Periyasamy","year":"2015","unstructured":"Periyasamy M, Patel H, Lai C-F, Nguyen VT, Nevedomskaya E, Harrod A, Russell R, Remenyi J, Ochocka AM, Thomas RS (2015) APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer. Cell Rep 13(1):108\u2013121","journal-title":"Cell Rep"},{"issue":"10","key":"5811_CR16","doi-asserted-by":"publisher","first-page":"e1601737","DOI":"10.1126\/sciadv.1601737","volume":"2","author":"EK Law","year":"2016","unstructured":"Law EK, Sieuwerts AM, LaPara K, Leonard B, Starrett GJ, Molan AM, Temiz NA, Vogel RI, Meijer-van Gelder ME, Sweep FC, Span PN, Foekens JA, Martens JW, Yee D, Harris RS (2016) The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv 2(10):e1601737. https:\/\/doi.org\/10.1126\/sciadv.1601737","journal-title":"Sci Adv"},{"issue":"2","key":"5811_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-018-5015-4","volume":"173","author":"JM Ryu","year":"2019","unstructured":"Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, Lee SK, Choi DH, Park YH, Kim JW, Seo JS, Park JH, Lee JE, Kim SW, Korean Hereditary Breast Cancer Study Group (2019) Prevalence and oncologic outcomes of BRCA 1\/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Res Treat 173(2):385\u2013395. https:\/\/doi.org\/10.1007\/s10549-018-5015-4","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05811-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T23:36:41Z","timestamp":1627256201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05811-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,26]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["5811"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05811-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,26]]},"assertion":[{"value":"19 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the Ethical Standards of the Institutional and\/or National Research Committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Boards of Seoul National University Bundang Hospital (Approval No. B-1711-430-301).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}